Intravitreal air tamponade after AAV2 subretinal injection modifies retinal EGFP distribution
Molecular Therapy - Methods & Clinical Development · 2023-03 · 28 · 387-393
DOI: 10.1016/j.omtm.2023.02.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2023-03. Verfasst von Jean-Baptiste Ducloyer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, CHU Nantes, INSERM, service d'ophtalmologie, TARGET, 44000 Nantes, France. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The subretinal injection protocol for the only approved retinal gene therapy (voretigene neparvovec-rzyl) includes air tamponade at the end of the procedure, but its effects on the subretinal bleb have not been described. In the present study, we evaluated the distribution of enhanced green fluorescent protein (EGFP) after subretinal injection of AAV2 in non-human primates (NHP) without (group A = 3 eyes) or with (group B = 3 eyes) air tamponade. The retinal expression of EGFP was assessed 1 month after subretinal injection with in vivo fundus photographs and fundus autofluorescence. In group A (without air), EGFP expression was limited to the area of the initial subretinal bleb. In group B (with air), EGFP was expressed in a much wider area. These data show that the buoyant force of air on the retina causes a wide subretinal diffusion of vector, away from the injection site. In the present paper, we discuss the beneficial and deleterious clinical effects of this finding. Whereas subretinal injection is likely to become more common with the coming of new gene therapies, the effects of air tamponade should be explored further to improve efficacy, reproducibility, and safety of the protocol.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nantes Université, CHU Nantes, INSERM, service d'ophtalmologie, TARGET, 44000 Nantes, France.
- Nantes Université, INSERM, TARGET, 44000 Nantes, France.
- Coave Therapeutics (formerly, Horama), 75012 Paris, France.
- Nantes Université, CNRS, CEISAM UMR 6230, 44000 Nantes, France.
Zitieren
APA
Ducloyer, J. B., Pichard, V., Mevel, M., Galy, A., Lefevre, G. M., Brument, N., Alvarez-Dorta, D., Deniaud, D., Mendes-Madeira, A., Libeau, L., Le Guiner, C., Cronin, T., Adjali, O., Weber, M., & Le Meur, G. (2023). Intravitreal air tamponade after AAV2 subretinal injection modifies retinal EGFP distribution. Molecular Therapy - Methods & Clinical Development, 28, 387-393. https://doi.org/10.1016/j.omtm.2023.02.006
Vancouver
Ducloyer JB, Pichard V, Mevel M, Galy A, Lefevre GM, Brument N, et al. Intravitreal air tamponade after AAV2 subretinal injection modifies retinal EGFP distribution. Molecular Therapy - Methods & Clinical Development. 2023;28:387-393. doi:10.1016/j.omtm.2023.02.006
BibTeX
@article{Ducloyer2023,
author = {Ducloyer, Jean-Baptiste and Pichard, Virginie and Mevel, Mathieu and Galy, Anne and Lefevre, Gaelle M and Brument, Nicole and Alvarez-Dorta, Dimitri and Deniaud, David and Mendes-Madeira, Alexandra and Libeau, Lyse and Le Guiner, Caroline and Cronin, Therese and Adjali, Oumeya and Weber, Michel and Le Meur, Guylène},
title = {Intravitreal air tamponade after AAV2 subretinal injection modifies retinal EGFP distribution},
journal = {Molecular Therapy - Methods & Clinical Development},
year = {2023},
volume = {28},
pages = {387--393},
doi = {10.1016/j.omtm.2023.02.006}
}
EUVIMED